Generated static export from Obsidian-friendly vault markdown
ClinPharm Vault

Briquilimab

Overview

  • Priority class: KIT
  • Mechanistic bucket: KIT-targeted mast-cell pathway program
  • Sponsor: Jasper Therapeutics, Inc.
  • Development focus: Active clinical development represented in current raw-source layer
  • Indications represented in current raw sources: Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Urticaria Chronic

Strategy readout

  • Headline: Earlier-stage KIT exploration across CSU and CIndU, with extension follow-up but no visible late-stage build yet.
  • Current strategic read: The current local stack suggests Jasper is using briquilimab to test KIT-driven benefit across both spontaneous and inducible disease, but the program remains meaningfully earlier than barzolvolimab in visible development maturity.
  • Highest visible phase in current registry: Phase 2
  • Strategy confidence in current local layer: Medium

Why this looks like the strategy

  • Separate dose-escalation studies exist for CSU and CIndU, which suggests intentional dual-indication exploration rather than a single narrow pilot.
  • The extension study indicates enough early interest to follow patients longer, but there is no phase 3 or manuscript-rich layer yet in the current cache.

What to watch next

  • Whether one phenotype becomes the clear lead path for registrational development.

Operational study design view

Trial Arms in registry Active dose regimens Total enrollment Per-arm sample size summary
NCT06162728 2 NR 88 88 total across 2 listed arms; exact arm-specific counts are not explicitly stated in the current local source text.
NCT06353971 1 1 27 Briquilimab n=27
NCT06736262 1 1 67 Briquilimab n=67

Study Inventory

Completed / historical studies

  • NCT06353971 - Phase 1, Phase 2; TERMINATED; Chronic Inducible Urticaria

Active / recruiting studies

  • NCT06162728 - Phase 1, Phase 2; ACTIVE_NOT_RECRUITING; Chronic Spontaneous Urticaria
  • NCT06736262 - Phase 2; ACTIVE_NOT_RECRUITING; Urticaria Chronic

Other registry entries

  • None in current registry

Evidence Coverage

  • CT.gov trials in registry: 3
  • Sponsor artifacts in registry: 1
  • Primary publications in registry: 0
  • Supporting publications in registry: 1
  • Publication status: supporting_only
  • Publication summary: No briquilimab-specific urticaria trial manuscript was identified in this PubMed pass. One broad KIT review hit was captured.

Primary publications

  • No primary publications currently linked in the registry

Supporting evidence

  • PMID 37897679: Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development. (raw/publications/pubmed/markdown/PMID37897679.md)
  • Sponsor artifact: Briquilimab program page (Jasper Therapeutics)
  • raw/sponsors/kit/briquilimab/briquilimab-program-page.html
  • raw/sponsors/kit/briquilimab/briquilimab-program-page.md

Interpretation

  • Verified facts: the current v2 registry tracks 3 CT.gov entries for this program and links them conservatively to sponsor and publication evidence where explicit identifiers are available.
  • Interpretation: this program is currently supported mainly by CT.gov and/or sponsor-source evidence, with weaker direct manuscript coverage in the local cache.
  • Open questions:
  • Several sponsor artifacts remain program-level because no explicit study identifier was captured in cached metadata.

Provenance

  • Primary source(s):
  • ../inventories/source_registry.json
  • ../inventories/source_registry.md
  • Supporting source(s):
  • ../inventories/ctgov_priority_trials.json
  • ../inventories/publication_priority_curation.json
  • ../inventories/sponsor_priority_sources.json
  • Last verified: 2026-04-08
  • Verification status: Partial

Change Log

  • 2026-04-08: Generated or refreshed this program page from the v2 source registry and local source caches.